Lamotrigine

• Epilepsy
• Bipolar Disorder
• Seizure Prevention
• Mood Stabilization

Lamotrigine is an anticonvulsant medication used for the treatment of epilepsy and bipolar disorder. This medication works through voltage-sensitive sodium channel blockade and offers unique benefits in bipolar disorder for preventing depressive episodes while having a favorable side effect profile.

Mechanism of Action

Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the presynaptic release of excitatory neurotransmitters, particularly glutamate. By blocking sodium channels in their inactivated state, lamotrigine preferentially reduces high-frequency repetitive firing of action potentials that occurs during seizure activity. The reduction in glutamate release may also contribute to its mood-stabilizing effects in bipolar disorder. Unlike some other mood stabilizers, lamotrigine's mechanism does not appear to involve significant effects on GABA transmission or monoamine neurotransmitter systems.

Available Formulations

Lamotrigine is available as immediate-release tablets (25 mg, 100 mg, 150 mg, 200 mg), chewable/dispersible tablets (2 mg, 5 mg, 25 mg), extended-release tablets (25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg), and orally disintegrating tablets (25 mg, 50 mg, 100 mg, 200 mg). Different formulations are not equivalent on a mg-per-mg basis. Generic formulations are available.

Medical Uses

Lamotrigine is FDA-approved for adjunctive therapy for seizures in patients aged 2 years and older with generalized seizures of Lennox-Gastaut syndrome, adjunctive therapy for primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset seizures, conversion to monotherapy in patients with partial-onset seizures receiving a single enzyme-inducing antiepileptic drug, and maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes. It is particularly effective in preventing depressive episodes in bipolar disorder.

Dosing Guidelines

Lamotrigine requires very slow dose titration to minimize the risk of serious rash. Initial doses and titration schedules vary significantly depending on whether the patient is taking enzyme-inducing anticonvulsants (e.g., carbamazepine, phenytoin) or valproate, which inhibits lamotrigine metabolism. For patients not taking these interacting drugs, typical starting dose is 25 mg daily for 2 weeks, then 50 mg daily for 2 weeks, with subsequent increases every 1-2 weeks. Maximum doses range from 200-500 mg daily depending on indication and concomitant medications.

Important Safety Information

Lamotrigine carries a boxed warning for serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal. The risk of serious rash is increased by rapid dose escalation, concurrent use of valproate, and exceeding initial recommended doses. Treatment should be discontinued at the first sign of rash unless clearly not drug-related. Other serious risks include hemophagocytic lymphohistiocytosis (HLH), multi-organ hypersensitivity reactions (DRESS), aseptic meningitis, and cardiac conduction abnormalities.

Drug Interactions

Valproate significantly increases lamotrigine levels (requires 50% dose reduction). Enzyme-inducing drugs (carbamazepine, phenytoin, phenobarbital, rifampin) significantly decrease lamotrigine levels (may require higher doses). Estrogen-containing oral contraceptives decrease lamotrigine levels; dose adjustment may be needed during the hormone-free week. Lamotrigine may decrease the efficacy of levonorgestrel-containing contraceptives.

Special Populations

Lamotrigine has data suggesting relatively safer use during pregnancy compared to some other anticonvulsants, though there is an increased risk of oral clefts with first trimester exposure. Plasma levels may change during pregnancy, requiring monitoring. It is excreted in breast milk; effects on nursing infants are unclear. Safety and efficacy have been established in pediatric patients aged 2 years and older for epilepsy. Elderly patients may require lower doses. Dose reduction is required in moderate and severe hepatic impairment. No dose adjustment is typically needed for renal impairment, though caution is advised in severe impairment.